Background: Lupus nephritis accounts for significant morbidity and mortality in patients with systemic lupus erythematosus (SLE). Many biomarkers for renal involvement in SLE have been suggested in Egyptian patients; one of them is Monocyte chemoattractant protein-1 (MCP-1) which is one of the key chemokines that has chemotactic effect for monocytes and macrophages to sites of inflammation and may share in the pathogenesis of lupus nephritis (LN).Aim: The study aimed at assessing the role of MCP-1 in the early diagnosis of lupus nephritis and to explore any correlation its levels with disease activity and renal status. Methods: The study was done as a case control study where 60 SLE patients with lupus nephritis (30 patients with active LN and 30 patients with inactive LN) in addition to 30 healthy volunteers as control group were enrolled in the study and MCP-1 levels was determined using ELISA technique.Results: The majority of the studied patients were females representing 93.33 % of the studied population. Urinary MCP-1 levels in overall SLE studied patients groups was significantly higher than its level in control group (P value 0.0001) and it was significantly higher in active LN than in non-active LN subgroups (P value =0.0001). and it is significantly associated with C3 , C4 and ACR. Conclusion: Urinary MCP-1 can be used as a marker for LN activity .Keywords: SLE , Lupus nephritis , MCP-1